Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 3:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: EB-101 Clear all
Active, not recruiting Phase 3 Interventional

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

NCT05725018
View directory record Official record
Conditions
Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB
Interventions
EB-101 Surgical application of RDEB wounds
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
12 Months and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Redwood City, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 16, 2026, 3:12 AM EDT
Enrolling by invitation No phase listed Observational

A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

NCT05708677
View directory record Official record
Conditions
RDEB
Interventions
EB-101
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
2
States / cities
Redwood City, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 16, 2026, 3:12 AM EDT
Completed Phase 3 Interventional

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT04227106
View directory record Official record
Conditions
Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Interventions
EB-101
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
6 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Redwood City, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 16, 2026, 3:12 AM EDT
Recruiting No phase listed Observational

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

NCT07700966
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Prademagene Zamikeracel
Combination Product
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2045
U.S. locations
4
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 16, 2026, 3:12 AM EDT